Results 241 to 250 of about 227,154 (335)

Eosinophilic Annular Erythema Induced by Bee Sting: A Case Report. [PDF]

Case Rep Dermatol
Xu A, Peng Q, Xiao Q, Wang X.
europepmc   +1 more source

Erythema Ab Igne in an Adolescent With Chronic Pain

, 2018
Sabrina Gmuca, JiaDe Yu, Pamela F. Weiss, James R. Treat, David D. Sherry   +4 more
openalex   +2 more sources

Scombroid and Anaphylaxis: Different Diseases Despite Featural Similarities. [PDF]

Cureus
Oliveira N, Junqueira V, Amorim R.
europepmc   +1 more source

PRIDE Complex (Papulopustules and/or Paronychia, Regulatory Abnormalities of Hair Growth, Itching, Dryness Due to EGFR Inhibitors)

JEADV Clinical Practice, EarlyView.
Sweta Subhadarshani, Brad R. Woodie, Taylor Griffith, Paul Andrew Bevins   +3 more
wiley   +1 more source

Erythema multiforme as the result of taking carbamazepine

, 2010
Maharani Laillyza Apriasari, M. Jusri
openalex   +2 more sources

The Crease Scale Sign as a Diagnostic Aid in Tinea Manuum

JEADV Clinical Practice, EarlyView.
Sunil Jaiswal, Shraddha Uprety, Pratichya Thapa, Prakriti Lamichhane   +3 more
wiley   +1 more source

Efficacy and safety of intradermal botulinum toxin A for post-acne erythema: a split-face randomized controlled trial. [PDF]

Front Med (Lausanne)
Yang L, Gao Y, Wu H, Li Y, Li C, Li X.
europepmc   +1 more source

Successful Treatment of Paediatric Necrobiosis Lipoidica With Baricitinib

JEADV Clinical Practice, EarlyView.
ABSTRACT Necrobiosis lipoidica (NL) is a rare, chronic granulomatous condition that typically presents as sharply demarcated plaques with telangiectasia and atrophic centres. Paediatric cases are uncommon, and treatment options often fail to address refractory cases.
P. Simões Farinha, M. J. Paiva‐Lopes
wiley   +1 more source

Diagnostic Disparities in Erythema Visibility: A Call to Redefine Inflammatory Assessment in Diverse Skin Tones. [PDF]

Cureus
Forsyth A, Prajapati S, Frasier KM, Kriebel C, Jackson T, Batista R, Jean F, Ezekwe U.   +7 more
europepmc   +1 more source

Clinically Meaningful Improvements in Quality of Life, Including Sleep, With Two‐Week and Monthly Dosed Rademikibart: A Phase 2 Randomized Trial in Adults With Moderate‐to‐Severe Atopic Dermatitis

JEADV Clinical Practice, EarlyView.
Rademikibart, a potent IL‐4Rα‐targeting antibody, achieved its primary endpoint as a treatment for adults with moderate‐to‐severe atopic dermatitis (AD) in the CBP‐201‐WW001 Phase 2 trial. There is a need for AD treatment options with convenient dosing intervals.
Jonathan I. Silverberg, Emma Guttman‐Yassky, Raúl Collazo   +2 more
wiley   +1 more source